Intervention-driven reduction in potentially inappropriate medication use amongst older adults in long-term care facilities in South Korea
In brief
Medication reviews held inappropriate medication use near 63%, while control rates rose to 76%
In a South Korean trial of 1,672 long-term care residents, the share taking potentially inappropriate medications fell from 65.8% to 62.5% with a multidisciplinary review program, while rising from 72.5% to 75.5% with usual care. Emergency visits and hospitalizations were numerically less frequent, but the difference was not significant, and the trial was not powered to assess these events.
- Journal
- Age and ageing (Q1)
- Published
- 31 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Ji-Hye Jung, Youn Huh, Sunmee Jang, Ju-Yeun Lee, Young-Mi Ah, Jung-Ha Kim
- PMID
- 43055511
- DOI
- 10.1093/ageing/afag331
Why clinicians should know about it
- Picked for Family Practice (paper of the day, 20 November 2026): Randomized deprescribing programme addresses older-adult polypharmacy
Abstract
BACKGROUND: Polypharmacy and potentially inappropriate medication (PIM) use are common in long-term care facilities (LTCFs) and are associated with adverse outcomes; evidence from Asian settings is limited. OBJECTIVE: To evaluate the effect of a multidisciplinary medication management programme on medication and PIM use and on serious adverse events (SAEs). DESIGN: Cluster randomised controlled trial in 28 LTCFs (16 intervention, 12 control). SETTING: LTCFs in the Seoul metropolitan area, South Korea. SUBJECTS: 1672 residents aged ≥65 years (836 per group). METHODS: Intervention facilities delivered comprehensive medication review, deprescribing recommendations and multidisciplinary case conferences; control facilities provided usual care. Assessments were made at baseline and at 3, 6, 9, 12 and 15 months. The number of PIMs and PIM user status were the primary outcomes; SAEs (falls, emergency department [ED] visits and hospitalisations) were pre-specified but not powered for. Medication outcomes were analysed with generalised linear mixed models and SAEs with Fine-Grey competing-risk models, both accounting for facility-level clustering and adjusted for 10 baseline covariates. RESULTS: Over 15 months, medication and PIM counts increased in the control but not the intervention group (time-by-group incidence rate ratio 0.993, 95% CI 0.990-0.996, P < .001, and .990, 0.983-0.997, P = .004). PIM users fell from 65.8% to 62.5% in the intervention arm and rose from 72.5% to 75.5% in the control arm (OR 0.981, 0.962-0.999, P = .043; not significant in the per-protocol analysis). ED visits or hospitalisations were less frequent in the intervention arm (27.6% vs 32.3%) but the difference was not significant (subdistribution hazard ratio 0.740, 0.493-1.112, P = .147); falls did not differ (P = .762). CONCLUSIONS: A multidisciplinary medication management programme was associated with reduced medication and PIM use. ED visits and hospitalisations were less frequent in the intervention arm, but not significantly so after accounting for facility-level clustering; the trial was not powered for these events and confirmation is needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.